Aptose Biosciences Files 8-K

Ticker: APTOF · Form: 8-K · Filed: Jul 1, 2025 · CIK: 882361

Sentiment: neutral

Topics: disclosure, financials, corporate-history

Related Tickers: APTO

TL;DR

APTO filed an 8-K on July 1st, standard disclosure update.

AI Summary

Aptose Biosciences Inc. filed an 8-K on July 1, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and operates in the Biological Products sector. The filing does not contain specific financial figures or event details beyond the reporting of these items.

Why It Matters

This filing indicates Aptose Biosciences Inc. is providing updated disclosures and financial information to the SEC, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any specific material events or financial distress.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Aptose Biosciences Inc.?

The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.

On what date was the earliest event reported in this filing?

The earliest event reported in this filing was on July 1, 2025.

What are the former names of Aptose Biosciences Inc. mentioned in the filing?

The filing mentions Aptose Biosciences Inc. was formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc.

In which jurisdiction is Aptose Biosciences Inc. incorporated?

Aptose Biosciences Inc. is incorporated in Canada.

What is the Standard Industrial Classification (SIC) code for Aptose Biosciences Inc.?

The SIC code for Aptose Biosciences Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 1, 2025 regarding Aptose Biosciences Inc. (APTOF).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing